
    
      The eligibility criteria were pathologically confirmed, previously untreated MCL or relapsed
      MCL as defined by the World Health Organization classification; age≥18 years; Eastern
      Cooperative Oncology Group (ECOG) performance status of 0-2; adequate haematologic function
      (haemoglobin > 9.0 g/l, absolute neutrophil count > 1500/ml, platelets > 75,000/l), hepatic
      function (total serum bilirubin ≤ 1.5 times the upper limit of normal, alanine
      aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper limit of normal), renal
      function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50 ml/min); normal coagulation
      function and electrocardiogram results. Stage was defined according to the Ann Arbor system.

      The Fujian Medical University Union Hospital approved this study before subjects were
      enrolled.

      Treatment dosages were as follows:

      days 1,4,8,and 11 subcutaneous infusion of 1.3mg/m2 Bortezomib. Days 1-3 intravenous infusion
      25mg/m2 Fludarabine. Days 1-3 intravenous infusion of 500mg/m2 Cytarabine. The regimen was
      repeated every 28 days for a maximum of six cycles.
    
  